If successful, it will expedite the concerted efforts to shut down oncogenic K-RAS-driven tumors using the next-generation of covalent K-RAS inhibitors to benefit pancreatic cancer patients in the future [79,113]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.